Psychotropic Receptor Modulation and Cognition in Psychotic Disorders
- 1Social Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK
Abstract
BackgroundCognitive impairment is a major determinant of functional outcome in psychotic disorders, yet the contribution of psychotropic medication is incompletely understood. This study aimed to determine whether personalised receptor-engagement profiles derived from prescribed psychotropic medications are associated with cognitive performance in individuals with psychotic disorders.
MethodsWe performed a cross-sectional study using clinical, cognitive, and medication data from the Bipolar-Schizophrenia Network on Intermediate Phenotypes studies. In 1,067 (51.5% female) individuals with psychotic disorders, we estimated personalised receptor-engagement profiles based on the prescribed dose and known pharmacological properties of 49 psychotropic medications across 32 drug targets. Correlated receptor-target modulation profiles were summarized into seven pharmacological clusters. Extreme gradient boosting models were trained using repeated nested cross-validation, with the contribution of pharmacological profiles to predicted cognition quantified using out-of-sample SHapley Additive exPlanations (SHAP) values. Overall pharmacological contribution was tested using within-diagnosis permutation testing.
ResultsEstimated receptor-engagement profiles were significantly associated with cognitive performance independent of diagnosis. A receptor profile involving alpha2-adrenergic, dopaminergic (DRD4, DRD5) and several serotonergic receptors was associated with poorer cognitive performance, whereas dopamine transporter (SLC6A3) engagement was associated with better cognitive performance. Muscarinic receptor modulation was additionally associated with poorer verbal memory and motor speed, while the DRD2-containing receptor profile was not associated with cognitive performance after correction for multiple testing.
ConclusionsModelling psychotropic medications according to receptor pharmacology identified receptor-engagement profiles associated with cognitive performance in psychotic disorders. This framework may help identify receptor systems for future investigation as potential targets for cognition-enhancing therapies and support the development of personalised prescribing strategies.
Related
- Long-Term Course of Loneliness in Psychotic Disorders
- Effect of ambient temperature and thermal comfort indices on emergency visits for psychotic and mood disorders: a case-crossover study in a French suburban area
- Ultra-rare coding variants in schizophrenia risk genes are associated with longitudinal phenotypic differences across psychotic disorders
- Psychotropic Drug Scheduling and Benzodiazepine Receptor Agonist Prescribing in Japan: An Interrupted Time Series Analysis
- The DMFT Index and Its Association with Psychiatric Symptom Severity among Inpatients with Psychotic Disorders
BibTeX
@misc{watson2026psychotropic,
title = {{Psychotropic Receptor Modulation and Cognition in Psychotic Disorders}},
author = {C. J. Watson and J. Hall and R. S. Keefe and P. McGuire and S. Natesan and M. Taquet and R. Upthegrove and J. T. Walters and T. Pillinger and R. A. McCutcheon},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.12.26365151},
url = {https://www.medrxiv.org/content/10.64898/2026.10.12.26365151v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Psychotropic Receptor Modulation and Cognition in Psychotic Disorders
AU - C. J. Watson
AU - J. Hall
AU - R. S. Keefe
AU - P. McGuire
AU - S. Natesan
AU - M. Taquet
AU - R. Upthegrove
AU - J. T. Walters
AU - T. Pillinger
AU - R. A. McCutcheon
PY - 2026
DA - 2026/10/12
PB - medRxiv
DO - 10.64898/2026.10.12.26365151
UR - https://www.medrxiv.org/content/10.64898/2026.10.12.26365151v1
AB - BackgroundCognitive impairment is a major determinant of functional outcome in psychotic disorders, yet the contribution of psychotropic medication is incompletely understood. This study aimed to determine whether personalised receptor-engagement profiles derived from prescribed psychotropic medications are associated with cognitive performance in individuals with psychotic disorders. MethodsWe performed a cross-sectional study using clinical, cognitive, and medication data from the Bipolar-Schizophrenia Network on Intermediate Phenotypes studies. In 1,067 (51.5% female) individuals with psychotic disorders, we estimated personalised receptor-engagement profiles based on the prescribed dose and known pharmacological properties of 49 psychotropic medications across 32 drug targets. Correlated receptor-target modulation profiles were summarized into seven pharmacological clusters. Extreme gradient boosting models were trained using repeated nested cross-validation, with the contribution of pharmacological profiles to predicted cognition quantified using out-of-sample SHapley Additive exPlanations (SHAP) values. Overall pharmacological contribution was tested using within-diagnosis permutation testing. ResultsEstimated receptor-engagement profiles were significantly associated with cognitive performance independent of diagnosis. A receptor profile involving alpha2-adrenergic, dopaminergic (DRD4, DRD5) and several serotonergic receptors was associated with poorer cognitive performance, whereas dopamine transporter (SLC6A3) engagement was associated with better cognitive performance. Muscarinic receptor modulation was additionally associated with poorer verbal memory and motor speed, while the DRD2-containing receptor profile was not associated with cognitive performance after correction for multiple testing. ConclusionsModelling psychotropic medications according to receptor pharmacology identified receptor-engagement profiles associated with cognitive performance in psychotic disorders. This framework may help identify receptor systems for future investigation as potential targets for cognition-enhancing therapies and support the development of personalised prescribing strategies.
ER -